Glaukos (GKOS) Financials: Revenue & Earnings
GKOS$236.10+54.67 +30.13%
$13.93B
Market Cap
-55.74
P/E
451.27
Forward P/E
50
Score
Glaukos (GKOS) Financials: Revenue & Earnings
GKOS price $236.10 +54.67 +30.13%
- Ticker
- GKOS
- Price
- $236.10
- Change
- +54.67 +30.13%
- Market cap ?
- $13.93B
- P/E ?
- -55.74
- Forward P/E ?
- 451.27
- Dividend yield ?
- 0.00%
- Beta ?
- 0.69
- Sector
- Healthcare
- Industry
- Medical - Devices
- Stocklytics score
- 50
- Value
- 35
- Quality
- 51
- Growth
- 64
Stocklytics score rationale: value 35, quality 51, growth 64.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 114397000 | 159254000 | 181278000 | 236984000 | 224959000 | 294011000 | 282862000 | 314711000 | 383481000 | 507442000 |
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat…
Earnings and financials
Glaukos Corporation (GKOS) trades at $236.10, with a market cap of $13.93B and a trailing P/E of -55.74. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 114397000 | 159254000 | 181278000 | 236984000 | 224959000 | 294011000 | 282862000 | 314711000 | 383481000 | 507442000 |
Insights · Dividends · Forecast · Financials · Learn